Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010838 | 1.00 | RAB9A (0.38) | RAB9APOLBL3MBTL1CHRNB2CHRNA7 | |
| SCHEMBL1665629 | 0.83 | POLB (0.41) | RAB9APOLBL3MBTL1CHRNB2CHRNA7 | |
| SCHEMBL1665632 | 0.83 | POLB (0.41) | RAB9APOLBL3MBTL1CHRNB2CHRNA7 | |
| SCHEMBL18710560 | 0.81 | HSD17B10 (0.45) | L3MBTL1 | |
| SCHEMBL15607552 | 0.77 | ACE2 (0.55) | L3MBTL1 | |
| SCHEMBL27988461 | 0.77 | PDE8B (0.44) | — | |
| SCHEMBL28063604 | 0.76 | CHRNB2 (0.38) | RAB9APOLBL3MBTL1CHRNB2CHRNA7 | |
| SCHEMBL16285121 | 0.76 | BTK (0.39) | POLBL3MBTL1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL12986221 | 0.76 | RAB9A (0.43) | RAB9APOLBL3MBTL1 | |
| SCHEMBL13195867 | 0.76 | RAB9A (0.43) | RAB9APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-7151182-B2 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-12-19 | — | — | US | disclosed |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2005-02-17 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | RAB9A 1909/4885POLB 4347/4885L3MBTL1 1502/4885 |
| US-20050038038-A1 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | RAB9A 1876/4885POLB 4340/4885L3MBTL1 1278/4885 |
| US-20050038075-A1 | Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, CPS1 | RAB9A 2161/4885POLB 3613/4885L3MBTL1 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.